The subject of the contract is the production of various iPS cells based on iPS Academia Japan patents. Takara Bio has already introduced production technology of cardiac muscle cells in cooperation with iHeart Japan Co., Ltd. in June this year, and since August 2014 cooperates with Cellectis AB Co. for technology to differentiate stem cells into liver cells and pancreatic cells (Takara has acquired the old Cellartis, Inc.).

Takara Bio news release, Nov. 4, 2014